Advances in HIV molecular biology

AIDS

Volumn 16, Issue SUPPL. 4, 2002, Pages

  Gummuluru, Suryaram ^a   Emerman, Michael ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Antiviral; Gag restriction; SiRNA; Vif

Indexed keywords

ANTIVIRUS AGENT; APOLIPOPROTEIN B; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; BINDING PROTEIN; CAPSID PROTEIN; COMPLEMENTARY DNA; CYTIDINE DEAMINASE; DOUBLE STRANDED RNA; ENVELOPE PROTEIN; FRIEND VIRUS SUSCEPTIBILITY 1 PROTEIN; GAG PROTEIN; GENE PRODUCT; IMMUNOGLOBULIN; MESSENGER RNA; POL PROTEIN; PROTEIN CA P2; PROTEIN CEM15; PROTEIN DERIVATIVE; PROTEIN DICER 1; PROTEIN HP68; PROTEIN INI1; REV PROTEIN; RNA DIRECTED DNA POLYMERASE; TRANSACTIVATOR PROTEIN; TRANSFER RNA; UNCLASSIFIED DRUG; VIF PROTEIN; VIRUS DNA; VIRUS RNA; VPU PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; B LYMPHOCYTE; CERCOPITHECIDAE; CHIMERA; CHIMPANZEE; DNA TEMPLATE; EXPERIMENTAL MODEL; GENE IDENTIFICATION; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LENTIVIRINAE; LIFE CYCLE; MACACA; MAMMAL; MOLECULAR BIOLOGY; MOLECULAR EVOLUTION; MOLECULAR WEIGHT; MURINE LEUKEMIA VIRUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; PROTEIN SYNTHESIS; RETROVIRUS; REVERSE TRANSCRIPTION; REVIEW; RNA CLEAVAGE; RNA DEGRADATION; RNA EDITING; RNA TRANSCRIPTION; SEQUENCE HOMOLOGY; SIMIAN IMMUNODEFICIENCY VIRUS; SPECIES DIFFERENCE; VIRION; VIROGENESIS; VIRUS ASSEMBLY; VIRUS GENOME; VIRUS IMMUNITY; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; EVOLUTION; GENE PRODUCTS, VIF; HIV-1; HUMANS; RNA INTERFERENCE; SPECIES SPECIFICITY; VIRUS REPLICATION;

EID: 0037000010     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200216004-00003     Document Type: Review

References (69)

1. Teodoro JG, and Branton PE. Regulation of apoptosis by viral gene products. J Virol 1997, 71:1739-1746.
2. Simon JH, Gaddis NC, Fouchier RA, Malim MH. Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med 1998, 4:1397-1400.
3. Madani N, Kabat D. An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J Virol 1998, 72:10251-10255.
4. Dettenhofer M, Yu XF. Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions. J Virol 1999, 73:1460-1467.
5. Bouyac M, Rey F, Nascimbeni M, et al. Phenotypically Vif- human immunodeficiency virus type 1 is produced by chronically infected restrictive cells. J Virol 1997, 71:2473-2477.
6. Fouchier RA, Simon JH, Jaffe AB, Malim MH. Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J Virol 1996, 70:8263-8269.
7. Goncalves J, Korin Y, Zack J, Gabuzda D. Role of Vif in human immunodeficiency virus type 1 reverse transcription. J Virol 1996, 70:8701-8709.
8. Ohagen A, Gabuzda D. Role of Vif in stability of the human immunodeficiency virus type 1 core. J Virol 2000, 74:11055-11066.
9. Simon JH, Malim MH. The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J Virol 1996, 70:5297-5305.
10. Simon JH, Carpenter EA, Fouchier RA, Malim MH. Vif and the p55(Gag) polyprotein of human immunodeficiency virus type 1 are present in colocalizing membrane-free cytoplasmic complexes. J Virol 1999, 73:2667-2674.
11. Khan MA, Aberham C, Kao S, et al. Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J Virol 2001, 75:7252-7265.
12. Dettenhofer M, Cen S, Carlson BA, et al. Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. J Virol 2000, 74:8938-8945.
13. Zhang H, Pomerantz RJ, Dornadula G, Sun Y. Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J Virol 2000, 74:8252-8261.
14. Sova P, Volsky DJ, Wang L, Chao W. Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag. J Virol 2001, 75:5504-5517.
15. Zimmerman C, Klein KC, Kiser PK, et al. Identification of a host protein essential for assembly of immature HIV-1 capsids. Nature 2002, 415:88-92.
16. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646-650.
17. Gerber AP, Keller W. RNA editing by base deamination: more enzymes, more targets, new mysteries. Trends Biochem Sci 2001, 26:376-384.
18. Cattaneo R, Kaelin K, Baczko K, Billeter MA. Measles virus editing provides an additional cysteine-rich protein. Cell 1989, 56:759-764.
19. Polson AG, Bass BL, Casey JL. RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase. Nature 1996, 380:454-456.
20. Arakawa H, Hauschild J, Buerstedde JM. Requirement of the activation-induced deaminase (AID) gene for immunoglobulin gene conversion. Science 2002, 295:1301-1306.
21. Muramatsu M, Kinoshita K, Fagarasan S, et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000, 102:553-563.
22. Petersen-Mahrt SK, Harris RS, Neuberger MS. AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature 2002, 418:99-103.
23. Bourara K, Litvak S, Araya A. Generation of G-to-A and C-to-U changes in HIV-1 transcripts by RNA editing. Science 2000, 289:1564-1566.
24. Kendrick JS, Chan L, Higgins JA. Superior role of apolipoprotein B48 over apolipoprotein B100 in chylomicron assembly and fat absorption: an investigation of apobec-1 knock-out and wild-type mice. Biochem J 2001, 356:821-827.
25. Simon JH, Miller DL, Fouchier RA, et al. The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: a role for Vif in determining virus host range and cross-species transmission. Embo J 1998, 17:1259-1267.
26. Mehta A, Kinter MT, Sherman NE, Driscoll DM. Molecular cloning of apobec-1 complementation factor, a novel RNA-binding protein involved in the editing of apolipoprotein B mRNA. Mol Cell Biol 2000, 20:1846-1854.
27. Muriaux D, Mirro J, Harvin D, Rein A. RNA is a structural element in retrovirus particles. Proc Natl Acad Sci USA 2001, 98:5246-5251.
28. Navaratnam N, Bhattacharya S, Fujino T, et al. Evolutionary origins of apoB mRNA editing: catalysis by a cytidine deaminase that has acquired a novel RNA-binding motif at its active site. Cell 1995, 81:187-195.
29. Hassaine G, Courcoul M, Bessou G, et al. The tyrosine kinase Hck is an inhibitor of HIV-1 replication counteracted by the viral vif protein. J Biol Chem 2001, 276:16885-16893.
30. Sharp PA. RNA interference-2001. Genes Dev 2001, 15:485-490.
31. Waterhouse PM, Wang MB, Lough T. Gene silencing as an adaptive defence against viruses. Nature 2001, 411:834-842.
32. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
33. Jacque J-M, Triques K, Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature 2002, 418:435-438.
34. Lee NS, Dohjima T, Bauer G, et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 2002, 20:500-505.
35. Hu W, Myers C, Kilzer J, et al. Inhibition of retroviral pathogenesis by RNA interference. Curr Biol 2002, 12:1301-1311.
36. Novina CD, Murray MF, Dykxhoorn DM, et al. A. siRNA-directed inhibition of HIV-1 infection. Nat Med 2002, 8:681-686.
37. Coburn GA, Cullen BR. Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J Virol 2002, 76:9225-9231.
38. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296:550-553.
39. Zeng Y, Wagner EJ, Cullen BR. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell 2002, 9:1327-1333.
40. Gitlin L, Karelsky S, Andino R. Short interfering RNA confers intracellular antiviral immunity in human cells. Nature 2002, 418:430-434.
41. Garrus JE, von Schwedler UK, Pornillos OW, et al. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 2001, 107:55-65.
42. Desrosiers RC. The simian immunodeficiency viruses. Ann Rev Immunol 1990, 8:557-578.
43. Shibata R, Sakai H, Kawamura M, et al. Early replication block of human immunodeficiency virus type 1 in monkey cells. J Gen Virol 1995, 76:2723-2730.
44. Shibata R, Kawamura M, Sakai H, et al. Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. J Virol 1991, 65:3514-3520.
45. Joag SV, Li Z, Foresman L, et al. Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques. J Virol 1996, 70:3189-3197.
46. Shiver JW, Liu MA, Letvin NL, Karlsson GB. Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys. J Immunol 1997, 158:4471-4477.
47. Li JT, Veazey R, Halloran M, et al. Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys. J Virol 1996, 70:6922-6928.
48. Emerman M, Malim MH. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science 1998, 280:1880-1884.
49. Besnier C, Takeuchi Y, Towers G. Restriction of lentivirus in monkeys. Proc Natl Acad Sci USA 2002, 99:11920-11925.
50. Cowan S, Hatziioannou T, Cunningham T, et al. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc Natl Acad Sci USA 2002, 99:11914-11919.
51. Dorfman T, Gottlinger HG. The human immunodeficiency virus type 1 capsid p2 domain confers sensitivity to the cyclophilin-binding drug SDZ NIM 811. J Virol 1996, 70:5751-5757.
52. Best S, Le Tissier P, Towers G, Stoye JP. Positional cloning of the mouse retrovirus restriction gene Fv1. Nature 1996, 382:826-829.
53. Bishop KN, Bock M, Towers G, Stoye JP. Identification of the regions of Fv1 necessary for murine leukemia virus restriction. J Virol 2001, 75:5182-8.
54. Bock M, Bishop KN, Towers G, Stoye JP. Use of a transient assay for studying the genetic determinants of Fv1 restriction. J Virol 2000, 74:7422-7430.
55. Jolicoeur P. The Fv-1 gene of the mouse and its control of murine leukemia virus replication. Curr Top Microbiol Immunol 1979, 86:67-122.
56. Forshey BM, von Schwedler U, Sundquist WI, Aiken C. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J Virol 2002, 76:5667-5677.
57. Fassati A, Goff SP. Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J Virol 2001, 75:3626-3635.
58. Courgnaud V, Pourrut X, Bibollet-Ruche F, et al. Characterization of a novel simian immunodeficiency virus from guereza colobus monkeys (Colobus guereza) in Cameroon: a new lineage in the nonhuman primate lentivirus family. J Virol 2001, 75:857-866.
59. Hofmann W, Schubert D, LaBonte J, et al. Species-specific, postentry barriers to primate immunodeficiency virus infection. J Virol 1999, 73:10020-10028.
60. LaBonte JA, Babcock GJ, Patel T, Sodroski J. Blockade of HIV-1 Infection of New World Monkey Cells Occurs Primarily at the Stage of Virus Entry. J Exp Med 2002, 196:431-445.
61. Gao G, Guo X, Goff SP. Inhibition of Retroviral RNA Production by ZAP, a CCCH-Type Zinc Finger Protein. Science 2002, 297:1703-1706.
62. Gottlinger HG. The HIV-1 assembly machine. AIDS 2001, 15 Suppl 5:S13-20.
63. Bieniasz PD, Cullen BR. Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells. J Virol 2000, 74:9868-9877.
64. Mariani R, Rutter G, Harris ME, et al. A block to human immunodeficiency virus type 1 assembly in murine cells. J Virol 2000, 74:3859-3870.
65. Mariani R, Rasala BA, Rutter G, et al. Mouse-human heterokaryons support efficient human immunodeficiency virus type 1 assembly. J Virol 2001, 75:3141-3151.
66. Kalpana GV, Marmon S, Wang W, et al. Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science 1994, 266:2002-2006.
67. Yung E, Sorin M, Pal A, Craig E, et al. Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1. Nat Med 2001, 7:920-926.
68. Freed EO. Viral late domains. J Virol 2002, 76:4679-4687.
69. Munk C, Brandt SM, Lucero G, Landau NR. A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc Natl Acad Sci USA 2002, 99:13843-13848.